Literature DB >> 24037469

Risk factors for mortality in AIDS-associated Kaposi sarcoma in a primary care antiretroviral treatment program in Malawi.

Kathryn Chu1, Dalitso Misinde, Moses Massaquoi, Olesi Pasulani, Beatrice Mwagomba, Nathan Ford, Rony Zachariah.   

Abstract

AIDS-associated Kaposi sarcoma (AIDS-KS) is the most common HIV-related malignancy. The majority of cases are found in sub-Saharan Africa. This retrospective cohort study describes characteristics of patients with AIDS-KS and factors associated with mortality in an antiretroviral treatment (ART) program in rural Malawi. Of 11 122 patients enrolled on ART, 830 (7%) had AIDS-KS. Patients with AIDS-KS were more likely to be lost to follow-up (22% versus 14%, P < 0.001) and showed a higher mortality (22% versus 10%, P < 0.001) compared to patients without AIDS-KS. A CD4 count ≤150 cells/μl, advanced stage AIDS-KS, and absence of bleomycin chemotherapy were associated with increased mortality. Earlier diagnosis and improved treatment of AIDS-KS are urgently needed in order to reduce mortality.

Entities:  

Year:  2010        PMID: 24037469     DOI: 10.1016/j.inhe.2010.04.001

Source DB:  PubMed          Journal:  Int Health        ISSN: 1876-3405            Impact factor:   2.473


  5 in total

1.  As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial.

Authors:  Mina C Hosseinipour; Minhee Kang; Susan E Krown; Aggrey Bukuru; Triin Umbleja; Jeffrey N Martin; Jackson Orem; Catherine Godfrey; Brenda Hoagland; Noluthando Mwelase; Deborah Langat; Mulinda Nyirenda; John MacRae; Margaret Borok; Wadzanai Samaneka; Agnes Moses; Rosie Mngqbisa; Naftali Busakhala; Otoniel Martínez-Maza; Richard Ambinder; Dirk P Dittmer; Mostafa Nokta; Thomas B Campbell
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

2.  Burden, characteristics, management and outcomes of HIV-infected patients with Kaposi's sarcoma in Zomba, Malawi.

Authors:  E Mwinjiwa; P Isaakidis; R Van den Bergh; A D Harries; K D Bezanson; T Beyene; C Thompson; M Joshua; H Akello; M van Lettow
Journal:  Public Health Action       Date:  2013-06-21

3.  Treatment outcomes of AIDS-associated Kaposi's sarcoma under a routine antiretroviral therapy program in Lilongwe, Malawi: bleomycin/vincristine compared to vincristine monotherapy.

Authors:  Albert A Mwafongo; Nora E Rosenberg; Wingston Ng'ambi; Alexandra B Werner; William M Garneau; Joe Gumulira; Sam Phiri; Mina C Hosseinipour
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

Review 4.  Marked sex differences in all-cause mortality on antiretroviral therapy in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Sarah W Beckham; Chris Beyrer; Peter Luckow; Meg Doherty; Eyerusalem K Negussie; Stefan D Baral
Journal:  J Int AIDS Soc       Date:  2016-11-08       Impact factor: 5.396

5.  Evaluation of a training intervention to improve cancer care in Zimbabwe: Strategies to Improve Kaposi Sarcoma Outcomes (SIKO), a prospective community-based stepped-wedge cluster randomized trial.

Authors:  Katherine R Sabourin; Margaret Borok; Samantha Mawhinney; Maxwell Matimba; Francis Jaji; Suzanne Fiorillo; Dickson D Chifamba; Claudios Muserere; Busisiwe Mashiri; Chenjerai Bhodheni; Patricia Gambiza; Rachael Mandidewa; Mercia Mutimuri; Ivy Gudza; Matthew Mulvahill; Camille M Moore; Jean S Kutner; Eric A F Simões; Thomas B Campbell
Journal:  J Int AIDS Soc       Date:  2022-08       Impact factor: 6.707

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.